Core domain mutation (S86Y) selectively inactivates polyubiquitin chain synthesis catalyzed by E2-25K.
The mammalian ubiquitin conjugating enzyme known as E2-25K catalyzes the synthesis of polyubiquitin chains linked exclusively through K48-G76 isopeptide bonds. The properties of truncated and chimeric forms of E2-25K suggest that the polyubiquitin chain synthesis activity of this E2 depends on specific interactions between its conserved 150-residue core domain and its unique 50-residue tail domain [Haldeman, M. T., Xia, G., Kasperek, E. M., and Pickart, C. M. (1997) Biochemistry 36, 10526-10537]. In the present study, we provide strong support for this model by showing that a point mutation in the core domain (S86Y) mimics the effect of deleting the entire tail domain: the ability to form an E2 approximately ubiquitin thiol ester is intact, while conjugation activity is severely inhibited (>/=100-fold reduction in kcat/Km). The properties of E2-25K enzymes carrying the S86Y mutation indicate that this mutation strengthens the interaction between the core and tail domains: both free and ubiquitin-bound forms of S86Y-25K are completely resistant to tryptic cleavage at K164 in the tail domain, whereas wild-type enzyme is rapidly cleaved at this site. Other properties of S86Y-26K suggest that the active site of this mutant enzyme is more occluded than the active site of the wild-type enzyme. (1) Free S86Y-25K is alkylated by iodoacetamide 2-fold more slowly than the wild-type enzyme. (2) In assays of E2 approximately ubiquitin thiol ester formation, S86Y-25K shows a 4-fold reduced affinity for E1. (3) The ubiquitin thiol ester adduct of S86Y-25K undergoes (uncatalyzed) reaction with dithiothreitol 3-fold more slowly than the wild-type thiol ester adduct. One model to accommodate these findings postulates that an enhanced interaction between the core and tail domains, induced by the S86Y mutation, causes a steric blockade at the active site which prevents access of the incoming ubiquitin acceptor to the thiol ester bond. Consistent with this model, the S86Y mutation inhibits ubiquitin transfer to macromolecular acceptors (ubiquitin and polylysine) more strongly than transfer to small-molecule acceptors (free lysine and short peptides). These results suggest that unique residues proximal to E2 active sites may influence specific function by mediating intramolecular interactions.
Mastrandrea
L D
LD
Department of Biochemistry, State University of New York, Buffalo 14214, USA.
Kasperek
E M
EM
Niles
E G
EG
Pickart
C M
CM
D000478:Alkylation; D019943:Amino Acid Substitution / Q000235:genetics; D000818:Animals; D001665:Binding Sites / Q000235:genetics; D001704:Biopolymers / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D002384:Catalysis; D002417:Cattle; D004789:Enzyme Activation / Q000187:drug effects / Q000235:genetics; D006801:Humans; D006868:Hydrolysis; D008025:Ligases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D016297:Mutagenesis, Site-Directed; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism; D010641:Phenotype; D017354:Point Mutation; D025821:Polyubiquitin; D017434:Protein Structure, Tertiary; D011817:Rabbits; D012694:Serine / Q000235:genetics*; D013329:Structure-Activity Relationship; D014357:Trypsin; D014443:Tyrosine / Q000235:genetics*; D044763:Ubiquitin-Conjugating Enzymes; D014452:Ubiquitins / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics
D001704:Biopolymers; D010446:Peptide Fragments; D014452:Ubiquitins; D025821:Polyubiquitin; D014443:Tyrosine; D012694:Serine; C100879:UBE2K protein, human; D044763:Ubiquitin-Conjugating Enzymes; D014357:Trypsin; D008025:Ligases